… Here, we investigated SR9009 effects on T98G cell viability, differential … it with the proteasome
inhibitor Bortezomib treatment. SR9009-treated cells exhibited significant reduction in cell …

… breast cancer chemotherapy and proteasome inhibitors) used as … eg, bortezomib and
cisplatin (as single) or eg, bortezomib+… Differential expression of DNAJB1 and HMOX1 (geometric …

… Proteasome inhibitors, such as bortezomib and carfilzomib, … proteomic landscape after
proteasome inhibition. Based on … treatments, and the differential expression became significant …

… the proteasome inhibitor bortezomib, since it represents a widely documented apoptotic inducer
in tumor cells [… only modest effects on the viability of differentiated Caco-2 cells that were …

… myeloma and mantle cell lymphoma xenograft models compared with the approved nonselective
proteasome inhibitors bortezomib and ixazomib. The differentiated preclinical profile of …

… proteasome inhibitor resistance, we engineered the breast … cells in the Lo19S state to withstand
bortezomib treatment (Fig. 2b… After 3 d, we assessed differential viability (Fig. 2c). Overall, …

… cells to the clinical drug bortezomib. A preliminary series of analogues elucidated critical
determinants of potency in proteasome inhibition… for factors such as differential cell permeability, …

… and cells on the lower side were fixed and stained with Diff … groups, but to date only Bortezomib,
Carfilzomib and Ixazomib are … While proteasome inhibition occurs similarly in the two cell …

… of the next generation of proteasome inhibitors in cancer therapies. … proteasome-associated
DUBs Breast cancer Ovarian cancer … These bortezomib-resistant cell lines displayed a cross-…

… bortezomib and carfilzomib in triple-negative breast cancer … the utility of proteasome
inhibitors in treating solid tumors, we … Then, differential expression of the genes was determined …